Apellis and Sobi Announce EMPAVELI^® (Pegcetacoplan) Showed Sustained Efficacy at One Year in Phase III Study for C3G and Primary IC-MPGN

Apellis Pharmaceuticals, Inc. presented new data from the open-label period of the Phase III VALIANT study, investigating EMPAVELI^® for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.